Abeona Therapeutics Inc. — FY 2015 Form 10-K
Reporting period: Fiscal year ended December 31, 2015; comparative figures are for FY 2014. This is an annual filing, not a standalone fourth-quarter report. Abeona focused on developing gene therapies and plasma-based treatments for rare diseases, alongside licensed MuGard products.
Financial performance and liquidity
| Metric | FY 2015 / Dec. 31, 2015 | FY 2014 / Dec. 31, 2014 |
|---|---|---|
| Total revenue | $1.040 million | $0.925 million |
| License revenue | $0.602 million | $0.598 million |
| Royalty revenue | $0.438 million | $0.327 million |
| Research and development expense | $4.715 million | $0.333 million |
| General and administrative expense | $14.320 million | $3.712 million |
| Total operating expenses | $19.586 million | $4.056 million |
| Loss from operations | $(18.546) million | $(3.131) million |
| Net loss allocable to common stockholders | $(14.526) million; $(0.53) per share | $(29.653) million; $(15.26) per share |
| Cash and cash equivalents | $40.138 million | $11.520 million |
| Working capital | $39.091 million | $8.657 million |
| Total liabilities | $12.334 million | $11.766 million |
Net cash used in operating activities was $10.423 million in 2015, compared with $1.611 million in 2014. Investing activities provided $3.389 million, primarily reflecting $3.697 million of cash acquired with Abeona Therapeutics LLC, partly offset by capital expenditures. Financing activities provided $35.652 million. The filing does not provide a clear gross-margin measure.
Year-end short-term notes payable were zero (2014: $0.400 million). Other significant liabilities included a $4.000 million payable to the plasma technology licensor, due in 2017 in cash or shares under the agreement, and $2.591 million of contingent consideration. The company reported an accumulated deficit of $310.6 million.
Material changes versus FY 2014
- Revenue increased by $0.115 million, primarily from higher MuGard royalties.
- R&D rose by $4.382 million as gene-therapy and plasma programs expanded. G&A rose by $10.608 million, including higher stock-based compensation, investor relations, legal and audit, staffing, and director costs.
- Operating loss widened substantially, while net loss allocable to common stockholders narrowed to $14.526 million from $29.653 million. The comparison is affected by the 2014 $23.110 million loss on the fair value of preferred-stock derivatives and $2.875 million of preferred dividends; preferred stock was converted into common stock in December 2014.
- Cash increased by $28.618 million, supported by 2015 equity financings and warrant exercises. The company issued 3,979,761 shares for the Abeona Ohio acquisition and completed multiple additional equity offerings, increasing dilution.
- The May 2015 acquisition brought in the Sanfilippo gene-therapy programs and recorded $32.466 million of goodwill. A missed first IND milestone reduced estimated contingent consideration and generated $3.898 million of miscellaneous income in 2015.
Outlook, risks, and unusual items
Management expected continued operating losses and substantial spending on research, preclinical work, clinical trials, and regulatory activities; no numerical earnings or revenue guidance was provided. The company stated it would need substantial additional capital and could need to delay, reduce, or eliminate programs if financing is unavailable. It did not expect significant near-term revenue from products or candidates.
- ABO-101 and ABO-102 were lead AAV gene-therapy candidates for Sanfilippo syndrome; ABO-201 targeted juvenile Batten disease, and ABO-301 targeted Fanconi anemia using a CRISPR/Cas9 approach. PTB-101 was the SDF-based alpha-1 protease inhibitor program. These candidates remained developmental at year-end.
- After year-end, the company reported regulatory clearances for planned Phase 1/2 Sanfilippo studies in Spain and FDA clearance of the ABO-102 IND in February 2016. These are subsequent events, not FY 2015 results.
- Key risks include clinical and regulatory failure or delay, limited operating revenue, dependence on external financing and collaborators, manufacturing and reimbursement uncertainty, competition, and patent or licensing challenges.
- The company reported no material pending legal proceedings and no material weakness in internal control over financial reporting. The auditor expressed an unqualified opinion on the financial statements; it did not audit internal-control effectiveness.
Important facts for investors to verify
- Confirm current cash, operating cash burn, financing needs, and the timing and terms of the $4.000 million licensor payment.
- Track clinical-trial initiation, enrollment, safety, and efficacy for ABO-101 and ABO-102, and distinguish post-year-end regulatory events from 2015 achievements.
- Review the sustainability and sources of MuGard royalty and licensing revenue, which totaled only $1.040 million in 2015.
- Assess potential dilution from outstanding warrants, options, future equity raises, and acquisition or licensing milestone obligations.
- Monitor the valuation and impairment risk of $32.466 million in goodwill and the contingent consideration liability, which depends on milestone outcomes.